- Home
- ZLAB vs RXRX Comparison
ZLAB vs RXRX Comparison
Compare ZLAB & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | RXRX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | RXRX |
|---|---|---|
| Price | $22.62 | $3.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $33.14 | $7.22 |
| AVG Volume (30 Days) | 712.3K | ★ 23.9M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | 14.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $74,681,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.50 | $34.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.33 | ★ 26.92 |
| 52 Week Low | $15.96 | $2.77 |
| 52 Week High | $30.00 | $7.18 |
Technical Indicators
Market Signals| Indicator | ZLAB | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 47.46 |
| Support Level | $16.97 | $2.90 |
| Resistance Level | $27.14 | $4.09 |
| Average True Range (ATR) | 1.03 | 0.35 |
| MACD | -0.36 | -0.06 |
| Stochastic Oscillator | 9.48 | 4.90 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.